Immunology in vogue

In vogue with venture

peptidase 4 (DPP4) inhibitor for type 2 diabetes. The compound looked to be safe and efficacious from the phase 2 trial results. However, it was barely differentiated from Merck’s (Whitehouse Station, New Jersey) Januvia (sitagliptin) and AstraZeneca’s (London) and Bristol-Myers Squibb’s (Princeton, New Jersey) Onglyza (saxagliptin). The company had a partnership already announced with a specia...

New models in vogue for circadian clocks

A recent flurry of activity among researchers who study circadian clocks has provided several significant advances in our knowledge of these daily timekeepers. Following the identification of new clock components, the establishment of new model systems, and more detailed information on the potential cogs, the mystery of the circadian clock may now be “on its knees” (Hall, 1995). The successful ...

VOGUE: Towards A Visual Interaction-aware Graph Query Processing Framework

Due to the complexity of graph query languages, the need for visual query interfaces that can reduce the burden of query formulation is fundamental to the spreading of graph data management tools to wider community. We present a novel hci (human-computer interaction)-aware graph query processing paradigm, where instead of processing a query graph after its construction, it interleaves visual qu...

VOGUE: The MoMuSys Video Object Generator with User Environment

The video object manipulation context set by the MPEG-4 standard has raised a need for respective content creation tools. This demand is expected to grow with the availability of MPEG-4 applications and devices in the marketplace as well as with the development of future content-based standards like MPEG-7, which is currently under development. In this paper a Video Object Generator with User E...

Immunology